DROSPIRENONE AND ETHINYL ESTRADIOL
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- DROSPIRENONE AND ETHINYL ESTRADIOL
- Generic name
- DROSPIRENONE AND ETHINYL ESTRADIOL
- Manufacturer
- Apotex Corp.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 9187a357-e95d-4733-9627-f19522b86373
- SPL ID
- 51c4495b-10a7-304e-e063-6394a90aa2ea
- Version
- 3
- Effective date
- 2026-05-14
- Source export date
- 2026-11-13
- Source partition
- 11
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/0ccebc9befe0ec22afe916211b2687f6eef8ed163963720f103786a7f2d2e3ae/drug-label-0011-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:30:33
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 207245 | derived:openfda.application_number |
| application number | ANDA207245 | openfda.application_number | |
| brand name | DROSPIRENONE AND ETHINYL ESTRADIOL | openfda.brand_name | |
| generic name | DROSPIRENONE AND ETHINYL ESTRADIOL | openfda.generic_name | |
| manufacturer name | Apotex Corp. | openfda.manufacturer_name | |
| ndc | package | 60505-4897-2 | openfda.package_ndc |
| ndc | package | 60505-4897-8 | openfda.package_ndc |
| ndc | product | 60505-4897 | openfda.product_ndc |
| ndc11 | package | 60505489702 | derived:openfda.package_ndc |
| ndc11 | package | 60505489708 | derived:openfda.package_ndc |
| rxcui | 748800 | openfda.rxcui | |
| rxcui | 748797 | openfda.rxcui | |
| rxcui | 284207 | openfda.rxcui | |
| spl id | 51c4495b-10a7-304e-e063-6394a90aa2ea | id | |
| spl set id | 9187a357-e95d-4733-9627-f19522b86373 | set_id |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning • Women over 35 years old who smoke should not use Drospirenone and Ethinyl Estradiol Tablets ( 4 ) • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 )].
boxed warning
WARNING TO WOMEN WHO SMOKE Do not use Drospirenone and Ethinyl Estradiol Tablets if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5.14 Other Conditions In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema. Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while taking COCs.
warnings and cautions table
<table width="100%"><caption/><tbody><tr><td><content styleCode="bold">Epidemiologic Study (Author, Year</content> <content styleCode="bold">of Publication) Population Studied</content></td><td><content styleCode="bold">Comparator Product (all are low-dose</content> <content styleCode="bold">COCs; with < 0.04 mg of EE)</content></td><td><content styleCode="bold">Hazard Ratio (HR) (95% CI) </content></td></tr><tr><td> i3 Ingenix (Seeger 2007) </td><td>All COCs available in the US during the conduct of the study <sup>b</sup></td><td> HR: 0.9 (0.5 - 1.6)</td></tr><tr><td> Initiators, including new users <sup>a</sup></td><td/><td/></tr><tr><td>EURAS (Dinger 2007) Initiators, including new users <sup>a</sup></td><td><paragraph>All COCs available in Europe during the conduct of the study <sup>c</sup></paragraph><paragraph/><paragraph>Levonorgestrel/EE</paragraph></td><td><paragraph>HR: 0.9 (0.6 - 1.4)</paragraph><paragraph/><paragraph/><paragraph>HR: 1.0 (0.6 - 1.8)</paragraph></td></tr><tr><td><paragraph> "FDA-funded study" (2011)</paragraph><paragraph>New users <sup>a</sup></paragraph><paragraph/><paragraph>All users (i.e., initiation and continuing use of study combination hormonal contraception)</paragraph></td><td><paragraph>Other COCs available during the course of the study <sup>d</sup></paragraph><paragraph/><paragraph>Levonorgestrel/0.03 mg EE</paragraph><paragraph/><paragraph>Other COCs available during the course of the study <sup>d</sup></paragraph><paragraph/><paragraph>Levonorgestrel/0.03 mg EE</paragraph></td><td><paragraph>HR: 1.8 (1.3 - 2.4)</paragraph><paragraph/><paragraph/><paragraph>HR: 1.6 (1.1 - 2.2)</paragraph><paragraph/><paragraph>HR: 1.7 (1.4 - 2.1)</paragraph><paragraph/><paragraph/><paragraph>HR: 1.5 (1.2 - 1.8)</paragraph></td></tr></tbody></table>
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: • Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ( 5.1 )] • Vascular events [see Warnings and Precautions ( 5.1 )] • Liver disease [see Warnings and Precautions ( 5.4 )] The most frequent adverse reactions (≥ 2%) are premenstrual syndrome (13.2%), headache /migraine (10.7%), breast pain/tenderness/discomfort (8.3%), nausea/vomiting (4.5%), abdominal pain/tenderness/discomfort (2.3%), mood changes (2.3%).( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice. The data provided reflect the experience with the use of Drospirenone and Ethinyl Estradiol Tablets (3 mg DRSP/0.03 mg EE) in the adequate and well-controlled studies for contraception (N=2,837). The US pivotal clinical study (N=326) was a multicenter, open-label trial in healthy women aged 18 to 35 who were treated for up to 13 cycles. The second pivotal study (N=442)was a multicenter, randomized, open-label comparative European study of Drospirenone and Ethinyl Estradiol Tablets vs. 0.150 mg desogestrel/0.03 mg EE conducted in healthy women aged 17 to 40 who were treated for up to 26 cycles. The most common adverse reactions (≥ 2% of users) were: premenstrual syndrome (13.2%), headache/migraine (10.7%), breast pain/tenderness/discomfort (8.3%), nausea/vomiting (4.5%) abdominal pain/discomfort/tenderness (2.3%) and mood changes (depression, depressed mood, irritability, mood swings, mood altered and affect lability (2.3%). Adverse Reactions (≥ 1%) Leading to Study Discontinuation: Of 2,837 women, 6.7% discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reaction leading to discontinuation was headache/migraine (1.5%). Serious Adverse Reactions: Depression, pulmonary embolism, toxic skin eruption, and uterine leiomyoma. 6.2 Postmarketing Experience Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 3). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 3). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use. Both of these studies found an increased risk of breast cancer with current use of longer duration, with relative risks ranging from 1.03 with less than one year of COC use to approximately 1.4 with more than 8-10 years of COC use. Figure 3: Relative Studies of Risk of Breast Cancer with Combined Oral Contraceptives Effect Estimate RR = relative risk; OR = odds ratio; HR = hazard ratio. “ever COC” are females with current or past COC use; “never COC use” are females that never used COCs. The following adverse reactions have been identified during post-approval use of Drospirenone and Ethinyl Estradiol Tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions, including fatalities, are grouped into System Organ Classes and ordered by frequency. Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, intracardiac thrombosis, intracranial venous sinus thrombosis, sagittal sinus thrombosis, retinal vein occlusion, myocardial infarction and stroke), hypertension Hepatobiliary disorders: Gallbladder disease Immune system disorders: Hypersensitivity Metabolism and nutrition disorders: Hyperkalemia Skin and subcutaneous tissue disorders: Chloasma figure 3
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.